drugset
drugset / Trial / NCT04575311

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

NCT04575311 ↗

Phase 1 Completed 32 enrolled Arcus Biosciences, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers.

Timeline

Start
2020-10-20
Primary completion
2021-09-22
Completion
2021-09-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quemliclustat Small molecule — Oral

Indications

No indication recorded.